Miriam Tendler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miriam Tendler has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Nilton Thaumaturgo
Laboratório de Esquistossomose Experimental, Departamento de Helmintologia, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
4 shared publicationsMônica Magno Vilar
Fiocruz Instituto Oswaldo Cruz Departamento de Helmintologia
3 shared publicationsRicardo Edelenyi
Fiocruz Instituto Oswaldo Cruz Departamento de Helmintologia
3 shared publicationsAndrew J. G. Simpson
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
2 shared publicationsAndrew Simpson
Orygen Biotecnologia, São Paulo, São Paulo, Brazil
2 shared publicationsCatia Maria Diogo
FIOCRUZ, Brasil
2 shared publications
Latest Publications
- Open Access
- 12 May 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 218
Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
Data herein reported and discussed refer to vaccination with the recombinant Fatty Acid Binding protein family member of the Schistosomes, called Sm14, discovered and developed under a Brazilian platform leaded by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, undertaken to assess safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14 based anti Schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide.
- 12 May 2015
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 6, 218
Open AccessDevelopment of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant
Data herein reported and discussed refer to vaccination with the recombinant Fatty Acid Binding protein family member of the Schistosomes, called Sm14, discovered and developed under a Brazilian platform leaded by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, undertaken to assess safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14 based anti Schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide.
- 18 July 2012
- Published by Wiley
- p. 435-449
Sm14 Schistosoma mansoni Fatty Acid‐Binding Protein: Molecular Basis for an Antihelminth Vaccine
- 18 July 2012
- Published by Wiley
- p. 435-449
Sm14 Schistosoma mansoni Fatty Acid‐Binding Protein: Molecular Basis for an Antihelminth Vaccine
- 1 November 2008
- Published by Elsevier in Acta Tropica
- Vol. 108 (2-3) , 263-266
The biotechnology-value chain: Development of Sm14 as a schistosomiasis vaccine
- 1 November 2008
- Published by Elsevier in Acta Tropica
- Vol. 108 (2-3) , 263-266
The biotechnology-value chain: Development of Sm14 as a schistosomiasis vaccine
- Open Access
- 1 June 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (6) , 3336-3343
RecombinantMycobacterium bovisBCG Expressing the Sm14 Antigen ofSchistosoma mansoniProtects Mice from Cercarial Challenge
The Sm14 antigen ofSchistosoma mansoniwas cloned and expressed inMycobacterium bovisBCG as a fusion with theMycobacterium fortuitumβ-lactamase protein under the control of its promoter, pBlaF*; the protein was localized in the bacterial cell wall. The rBCG-Sm14 strain was shown to be relatively stable in cultured murine and bovine monocytes in terms of infectivity, bacterial persistence, and plasmid stability. The immunization of mice with rBCG-Sm14 showed no induction of anti-Sm14 antibodies; however, splenocytes of immunized mice released increased levels of gamma interferon upon stimulation with recombinant Sm14 (rSm14), indicating an induction of a Th1-predominant cellular response against Sm14. Mice immunized with one or two doses of rBCG-Sm14 and challenged with liveS. mansonicercaria showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of rSm14 purified fromEscherichia coli. The data presented here further enhance the status of Sm14 as a promising candidate antigen for the control of schistosomiasis and indicate that a one-dose regimen of rBCG-Sm14 could be considered a convenient means to overcome many of the practical problems associated with the successful implementation of a multiple-dose vaccine schedule in developing countries.
- 1 June 2004
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 72 (6) , 3336-3343
Open AccessRecombinantMycobacterium bovisBCG Expressing the Sm14 Antigen ofSchistosoma mansoniProtects Mice from Cercarial Challenge
The Sm14 antigen ofSchistosoma mansoniwas cloned and expressed inMycobacterium bovisBCG as a fusion with theMycobacterium fortuitumβ-lactamase protein under the control of its promoter, pBlaF*; the protein was localized in the bacterial cell wall. The rBCG-Sm14 strain was shown to be relatively stable in cultured murine and bovine monocytes in terms of infectivity, bacterial persistence, and plasmid stability. The immunization of mice with rBCG-Sm14 showed no induction of anti-Sm14 antibodies; however, splenocytes of immunized mice released increased levels of gamma interferon upon stimulation with recombinant Sm14 (rSm14), indicating an induction of a Th1-predominant cellular response against Sm14. Mice immunized with one or two doses of rBCG-Sm14 and challenged with liveS. mansonicercaria showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of rSm14 purified fromEscherichia coli. The data presented here further enhance the status of Sm14 as a promising candidate antigen for the control of schistosomiasis and indicate that a one-dose regimen of rBCG-Sm14 could be considered a convenient means to overcome many of the practical problems associated with the successful implementation of a multiple-dose vaccine schedule in developing countries.
- 1 March 2003
- Published by Wiley in Parasite Immunology
- Vol. 25 (3) , 135-137
Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14
SUMMARY: Fasciola hepatica is the causative agent of fasciolosis in many areas in America, Europe, Africa, Asia and Australia. There is an urgent need for improved methods to control the parasite's transmission. We describe the use of an experimental vaccine based on a recombinant antigen cloned from another parasite, Schistosoma mansoni (Sm14), that induces high levels of cross protection in mice against both S. mansoni and F. hepatica. Sheep and mice vaccinated with Sm14 were significantly protected against challenge infection with metacercariae of Fasciola hepatica and were completely free of the histopathological hepatic damage related to liver fluke infection. The vaccine will provide a valuable new tool to aid in transmission control of this economically important disease.
- 1 March 2003
- Published by Wiley in Parasite Immunology
- Vol. 25 (3) , 135-137
Vaccination against Fasciola hepatica infection using a Schistosoma mansoni defined recombinant antigen, Sm14
SUMMARY: Fasciola hepatica is the causative agent of fasciolosis in many areas in America, Europe, Africa, Asia and Australia. There is an urgent need for improved methods to control the parasite's transmission. We describe the use of an experimental vaccine based on a recombinant antigen cloned from another parasite, Schistosoma mansoni (Sm14), that induces high levels of cross protection in mice against both S. mansoni and F. hepatica. Sheep and mice vaccinated with Sm14 were significantly protected against challenge infection with metacercariae of Fasciola hepatica and were completely free of the histopathological hepatic damage related to liver fluke infection. The vaccine will provide a valuable new tool to aid in transmission control of this economically important disease.
- Open Access
- 1 October 2002
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 97 (suppl 1) , 115-116
Characterization of Sm14 related components in different helminths by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis
Sm14 was the first fatty acid-binding protein homologue identified in helminths. Thereafter, members of the same family were identified in several helminth species, with high aminoacid sequence homology between them. In addition, immune crossprotection was also reported against Fasciola hepatica infection, in animals previously immunized with the Schistosoma mansoni vaccine candidate, r-Sm14. In the present study, data on preliminary sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis of nine different helminth extracts focusing the identification of Sm14 related proteins, is reported. Out of these, three extracts - Ascaris suum (males and females), Echinostoma paraensei, and Taenia saginata - presented components that comigrated with Sm14 in SDS-PAGE, and that were recognized by anti-rSm14 policlonal serum, in Western blotting tests.
- 1 October 2002
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 97 (suppl 1) , 115-116
Open AccessCharacterization of Sm14 related components in different helminths by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis
Sm14 was the first fatty acid-binding protein homologue identified in helminths. Thereafter, members of the same family were identified in several helminth species, with high aminoacid sequence homology between them. In addition, immune crossprotection was also reported against Fasciola hepatica infection, in animals previously immunized with the Schistosoma mansoni vaccine candidate, r-Sm14. In the present study, data on preliminary sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting analysis of nine different helminth extracts focusing the identification of Sm14 related proteins, is reported. Out of these, three extracts - Ascaris suum (males and females), Echinostoma paraensei, and Taenia saginata - presented components that comigrated with Sm14 in SDS-PAGE, and that were recognized by anti-rSm14 policlonal serum, in Western blotting tests.
- Open Access
- 1 September 2001
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 96 (suppl) , 79-83
Preliminary analysis of Sm14 in distinct fractions of Schistosoma mansoni adult worm extract
In previous studies it was shown that the recombinant molecule, r-Sm14, induces high levels of protection against Schistosoma mansoni infection in two outbred animal models and immune crossprotection against infection by Fasciola hepatica in Swiss outbred mice. r-Sm14 was derived from a living worm extract, called SE, and is being developed as the molecular basis of an anti-helminth bivalent vaccine against the two parasites, for medical and veterinary application. Present data refer to SDS-PAGE and Western Blotting analysis of four different preparations of S. mansoni adult worms focusing Sm14 identification. The extracts correspond to the initial fraction of the SE extraction process, containing products released by living worms (SEi); SE2, reextraction of adult worms in PBS; and SE of separated male and female adult worms. In all extracts it was possible to detect the component of 14 kDa, that was recognized by specific anti-rSm14 antibody raised in rabbits.
- 1 September 2001
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 96 (suppl) , 79-83
Open AccessPreliminary analysis of Sm14 in distinct fractions of Schistosoma mansoni adult worm extract
In previous studies it was shown that the recombinant molecule, r-Sm14, induces high levels of protection against Schistosoma mansoni infection in two outbred animal models and immune crossprotection against infection by Fasciola hepatica in Swiss outbred mice. r-Sm14 was derived from a living worm extract, called SE, and is being developed as the molecular basis of an anti-helminth bivalent vaccine against the two parasites, for medical and veterinary application. Present data refer to SDS-PAGE and Western Blotting analysis of four different preparations of S. mansoni adult worms focusing Sm14 identification. The extracts correspond to the initial fraction of the SE extraction process, containing products released by living worms (SEi); SE2, reextraction of adult worms in PBS; and SE of separated male and female adult worms. In all extracts it was possible to detect the component of 14 kDa, that was recognized by specific anti-rSm14 antibody raised in rabbits.
- Open Access
- 1 September 2001
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 96 (suppl) , 131-135
r-Sm14 - pRSETA efficacy in experimental animals
Previous studies carried out with Sm14 in experimental vaccination against Schistosoma mansoni or Fasciola hepatica infections were performed with recombinant Sm14 (rSm14) produced in Escherichia coli by the pGEMEX system (Promega). The rSm14 was expressed as a 40 kDa fusion protein with the major bacteriophage T7 capsid protein. Vaccination experiments with this rSm14 in animal models resulted in consistent high protective activity against S. mansoni cercariae challenge and enabled rSm14 to be included among the vaccine antigens endorsed by the World Health Organization for phase I/II clinical trials. Since the preparation of pGEMEX based rSm14 is time consuming and results in low yield for large scale production, we have tested other E. coli expression systems which would be more suitable for scale up and downstream processing. We expressed two different 6XHis-tagged Sm14 fusion proteins in a T7 promoter based plasmids. The 6XHis-tag fusions allowed rapid purification of the recombinant proteins through a Ni+2-charged resin. The resulted recombinant 18 and 16 kDa proteins were recognized by anti-Sm14 antibodies and also by antiserum against adult S. mansoni soluble secreted/excreted proteins in Western-Blot. Both proteins were also protective against S. mansoni cercariae infection to the same extent as the rSm14 expressed by the pGEMEX system.
- 1 September 2001
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 96 (suppl) , 131-135
Open Accessr-Sm14 - pRSETA efficacy in experimental animals
Previous studies carried out with Sm14 in experimental vaccination against Schistosoma mansoni or Fasciola hepatica infections were performed with recombinant Sm14 (rSm14) produced in Escherichia coli by the pGEMEX system (Promega). The rSm14 was expressed as a 40 kDa fusion protein with the major bacteriophage T7 capsid protein. Vaccination experiments with this rSm14 in animal models resulted in consistent high protective activity against S. mansoni cercariae challenge and enabled rSm14 to be included among the vaccine antigens endorsed by the World Health Organization for phase I/II clinical trials. Since the preparation of pGEMEX based rSm14 is time consuming and results in low yield for large scale production, we have tested other E. coli expression systems which would be more suitable for scale up and downstream processing. We expressed two different 6XHis-tagged Sm14 fusion proteins in a T7 promoter based plasmids. The 6XHis-tag fusions allowed rapid purification of the recombinant proteins through a Ni+2-charged resin. The resulted recombinant 18 and 16 kDa proteins were recognized by anti-Sm14 antibodies and also by antiserum against adult S. mansoni soluble secreted/excreted proteins in Western-Blot. Both proteins were also protective against S. mansoni cercariae infection to the same extent as the rSm14 expressed by the pGEMEX system.
- Open Access
- 1 April 1995
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 90 (2) , 255-256
Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent anti-helminth vaccine?
Molecular cloning of components of protective antigenic preparations have suggested that related parasite fatty acid binding proteins could form the basis of the well documented protective, immune cross reactivity between the parasitic trematode worms Fasciola hepatica and Schistosoma mansoni. We have now confirmed the cross protective potential of parasite fatty acid binding proteins and suggest that it may be possible to produce a single vaccine that would be effective against at least two parasites, F. hepatica and S. mansoni of veterinary and human importance respectively.
- 1 April 1995
- Published by FapUNIFESP (SciELO) in Memórias do Instituto Oswaldo Cruz
- Vol. 90 (2) , 255-256
Open AccessVaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent anti-helminth vaccine?
Molecular cloning of components of protective antigenic preparations have suggested that related parasite fatty acid binding proteins could form the basis of the well documented protective, immune cross reactivity between the parasitic trematode worms Fasciola hepatica and Schistosoma mansoni. We have now confirmed the cross protective potential of parasite fatty acid binding proteins and suggest that it may be possible to produce a single vaccine that would be effective against at least two parasites, F. hepatica and S. mansoni of veterinary and human importance respectively.